What if the deadliest complication in pregnancy could be caught early… with just a single drop of blood?
In 2025, we are still telling women to “wait and see” while their organs shut down.
In this episode of Blindspot Capital, I sit down with Matthias Wipf, CEO of MOMM Diagnostics, whose company has developed a rapid test for preeclampsia that could transform maternal care globally.
We talk science, fundraising bias, and why women’s health innovations still get sidelined even when lives are on the line.
Watch now to see why a condition affecting millions of pregnant women still lacks a reliable diagnostic and what it will take to change that.
🎧 Watch Full episode on YouTube or wherever you get your podcast.
About MOMM Diagnostics:
Founded in 2018, MOMM Diagnostics is reimagining maternal care with préXclude, a breakthrough test for early detection of preeclampsia. With just a drop of blood and a few minutes, their technology gives clinicians the power to act before pregnancy complications become emergencies. Born out of research collaborations in Switzerland and California, MOMM is part of a new wave of founders who are turning overlooked health problems into high-impact innovation. Learn more here.
Share this post